Peer-reviewed veterinary case report
New peptide treatment targets bacteria in dog skin infections
By Greco, Ines et al.·Published in Scientific reports·2019·Department of Drug Design and Pharmacology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Characterization, mechanism of action and optimization of activity of a novel peptide-peptoid hybrid against bacterial pathogens involved in canine skin infections.
- Species:
- dog
Plain-English summary
A study found a new treatment option for dogs with skin infections caused by tough bacteria like Staphylococcus pseudintermedius and Pseudomonas aeruginosa. These infections, often seen as pyoderma, can be hard to treat due to antibiotic resistance. The new peptide-peptoid hybrid, called B1, showed strong effectiveness against these bacteria in lab tests, disrupting their cell membranes and stopping their growth. This could help reduce the need for stronger human antibiotics in treating dogs. Further research is needed, but this could be a promising step toward developing targeted treatments for canine skin infections.
People also search for: dog skin infection treatment · pyoderma in dogs · antibiotic resistance in dogs
Abstract
Integumentary infections like pyoderma represent the main reason for antimicrobial prescription in dogs. Staphylococcus pseudintermedius and Pseudomonas aeruginosa are frequently identified in these infections, and both bacteria are challenging to combat due to resistance. To avoid use of important human antibiotics for treatment of animal infections there is a pressing need for novel narrow-spectrum antimicrobial agents in veterinary medicine. Herein, we characterize the in vitro activity of the novel peptide-peptoid hybrid B1 against canine isolates of S. pseudintermedius and P. aeruginosa. B1 showed potent minimum inhibitory concentrations (MICs) against canine S. pseudintermedius and P. aeruginosa isolates as well rapid killing kinetics. B1 was found to disrupt the membrane integrity and affect cell-wall synthesis in methicillin-resistant S. pseudintermedius (MRSP). We generated 28 analogues of B1, showing comparable haemolysis and MICs against MRSP and P. aeruginosa. The most active analogues (23, 26) and B1 were tested against a collection of clinical isolates from canine, of which only B1 showed potent activity. Our best compound 26, displayed activity against P. aeruginosa and S. pseudintermedius, but not the closely related S. aureus. This work shows that design of target-specific veterinary antimicrobial agents is possible, even species within a genus, and deserves further exploration.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30842436/